Related Experiment Video
Updated: Jun 10, 2026

Intravenous and Intra-amniotic In Utero Transplantation in the Murine Model
Published on: October 9, 2018
Congenital fetal heart block: a potential therapeutic role for intravenous immunoglobulin
Anna L David1, Ifat Ataullah, Rob Yates
1From the Institute for Women's Health, University College London Hospitals; the Cardiac Unit, Great Ormond Street Hospital for Children NHS Trust; and the Division of Immunology, Hammersmith Hospitals NHS Trust, London, United Kingdom.
Background:
Congenital heart block affects 2% of all mothers with anti-Ro/La antibodies, can cause heart failure in utero, and has a 20% mortality rate in the first 3 years of life. Maternal fluorinated steroids to prevent or reverse congenital heart block can cause pregnancy complications. Intravenous immunoglobulin (IVIG) has been given with maternal steroids to prevent the recurrence of congenital heart block, although its efficacy is unproven.
Case:
We report the use of IVIG to prevent progression of 2:1 congenital heart block with intermittent complete heart block. After two maternal infusions of IVIG (0.4 g/kg) at 31 weeks of gestation, the fetal heart rate reverted to long periods of sinus rhythm, which was sustained until postnatal life.
Conclusion:
Our case supports investigating IVIG in the prevention or treatment of this life-threatening condition.
Related Concept Videos
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Heart Failure Drugs: Inotropic Agents
Myocarditis III: Medical Management
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Myocarditis IV: Nursing Management
